Concordia Healthcare to Present at Bloom Burton & Co. Healthcare Investor Conference

TORONTO, June 12, 2014 /CNW/ - Concordia Healthcare Corp. (TSX: CXR) (OTCQX: CHEHF), today announced that Mark Thompson, Chief Executive Officer, will present at the 2014 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario. Concordia's presentation will take place on Wednesday, June 18, 2014, at 11:00 a.m. ET.

Bloom Burton's third annual healthcare investor conference features Canada's premier publicly-traded and venture-backed private companies. The event will attract Canadian, U.S. and European investors who are interested in the latest developments in Canadian healthcare companies.

About Concordia

Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. The Company's legacy pharmaceutical business consists of Donnatal^®, an adjunctive therapy in the treatment of IBS and acute enterocolitis, an ADHD-treatment drug, Kapvay^® (clonidine extended release tablets), Ulesfia^® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT^® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin^® in the United States.

Concordia operates out of facilities in Oakville, Ontario, Bridgetown, Barbados, Lenexa, Kansas (near Kansas City, Missouri), Bannockburn (near Chicago), Illinois, and Charlottesville, Virginia.

SOURCE: Concordia Healthcare Corp.

Please visit www.concordiarx.com or contact:

Kristen van Vogt
TMX Equicom
416-815-0700 x 244
[email protected]

Adam Peeler
TMX Equicom
416-815-0700 x 225
[email protected]